PPARG and cancer: Outside BRAFV600E, the likelihood of cancer for those variants documented as positive in at least 10 nodules in the included studies (BRAFK601E, HRASq61R, NRASq61R, and PAX8/PPARG fusion) ranged from 37% to 55%.